Filing Flows › Veracyte (VCYT) › Q2 2025
Veracyte (VCYT) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Veracyte (VCYT) reported revenue of $130M for the second quarter 2025 (Q2 2025), +14% from a year earlier and +14% from the quarter before. Operating margin was -4.0%, net loss $980K (0.8% of revenue).
Veracyte, Q2 2025: revenue $130M (+14% year over year), operating margin -4.0%, net loss $980K, operating cash flow $33.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $130M | +14% | +14% |
| Operating profit | −$5.3M | -281% | — |
| Net earnings | −$980K | -114% | — |
| Operating cash flow | $33.6M | +527% | +14% |
| Free cash flow | $32.3M | +812% | +21% |
What changed
Revenue was $130.2M in Q2 2025, up 14% year over year and up 14% from the previous quarter. Testing revenue was the largest line at 94% of revenue. Testing revenue added $15.3M year over year (up 14%), 97% of the total change. Other Testing Revenue declined 55%.
Gross margin was 69.0%, up 0.9 points from a year earlier. Operating costs exceeded revenue by $5.3M, an operating margin of -4.0%. Operating expenses grew 30% against revenue growth of 14%. The fastest-growing cost line was Other operating costs (+2298%). The quarter ended with a net loss of $1.0M, after a profit of $7.0M the previous quarter. Non-operating items added $6.5M, 521% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $33.6M (up 14% year over year). Non-cash charges added back $5.5M of depreciation and amortization and $11.0M of share-based compensation. Working capital and other items added $18.1M. Capital expenditures of $1.3M left free cash flow of $32.3M.
Questions
What was Veracyte's revenue in the second quarter 2025?
Veracyte (VCYT) reported revenue of $130M for the second quarter 2025 (Q2 2025), +14% from a year earlier and +14% from the quarter before.
Was Veracyte profitable in the second quarter 2025?
Operating loss was $5.3M (-4.0% of revenue) and net loss $980K.
Source: Veracyte 10-Q on SEC EDGAR.